China Pharma IP Summit is a serial event dedicated to pharmaceutical IP protection, and so far we have hold 2 sessions in the year of 2016 and 2017. Government agencies, pharmaceutical/biotech companies, law firms/ IP agencies and other IP solution providers have been invited to attend and we discussed lots of hot issues. Meanwhile, the event has been a good networking platform for industry experts both from local China and abroad.

2017 is a year of great significance in China pharmaceutical industry. On May 2017, China Food and Drug Administration (CFDA) issued Policy Notice No. 55, entitled “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued, clearly putting forward the establishing patent linkage system, launching pilot program on drug patent extension, completing data protection and implementing list of marketed drugs. At the moment, China is conducting legislation for patent linkage and patent extension, which draws lots of attention.

In terms of intellectual property judicial, on Feb 2018, General Office of the CPC and General Office of the State Council issued Strengthening the Intellectual Property Judicial Reform and Innovation, which is the first guiding document regarding to intellectual property judicial. Pharmaceutical is heavily relied on IP protection, and we predict the guiding document will have influence on pharmaceutical IP litigation in China.

Based on the background, we are glad to inform that 3rd China Pharma IP Summit 2018 will be hold on 24th -26th October in Beijing, providing a platform to discuss updated policies and hot issues.

Through the event, you will have chance to:

1. Follow the latest development of patent linkage and patent term extension reform in China

2. Understand the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other region.

3. Learn IP management experience from pharmaceutical company

4. Meet you clients/partners fact to face and interact with industry peers

The participants are mainly from pharma/biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!


Day1:24, Oct. 2018
Day1 Morning: Policies Updated in China

0730 Registration

0830 Chairman Opening Remarks


Interpretation of the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation and the Latest Supportive Documents

China Food and Drug Administration (inviting)


The Latest Development of Patent Term Extension Reform in China

CFDA is conducting legislation for patent term extension reform, and the pilot program is expected to be launched within this year. We will invite expert to share the latest development, including the product and patent scope for patent extension, the condition for extension, the extension period calculation and the opposition proceedings and so on.

Speaker is inviting

Coffee Break


Updated Implementation Rules for Patent Linkage System in China

You can tell China government is devoted to pushing the establishment of patent linkage: on May 2017, CFDA issued “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued. On December 2017, the first edition of List of Marketed Medicine was released. Hopefully, more detailed implementation rules are expected to be released as CFDA is also conducting legislation for patent linkage.

Speaker is inviting


Topic Is Confirming



The Patent Linkage for Pharmaceuticals -A Worldwide Perspective

Yehudah Livneh, Strategic IP Consultant;

Former General Patent Counsel and VP Corporate IP and Legislative Affairs, Teva Pharmaceuticals

1240 Lunch Buffet

Day 1 Afternoon: Focus on US


Recent US Legal Developments and How These Developments Are Affecting The Pharmaceutical Companies

Philip Johnson, Found and Principal of Johnson-IP Strategy and Consulting;
Former SVP- IP Policy & Strategy of Johnson & Johnson – Law Department (retired in 2017)


Topic is Confirming

Shashank Upadhye, Founding Partner, Amin Talati Upadhye, LLP


The ANAD Litigation Comparison Between China Generic and India Generic in US



Coffee Break


Development and Implication of Para IV Litigation Cases in US

Christopher Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP


Topic is Confirming

Alyson Wooten, Counsel, Kilpatrick Townsend & Stockton LLP


Q&A Session: Practical Tips for Litigation in US

In the afternoon, we introduce the examination, litigation in US, but we think participants still have questions need to be answered. We will invite in-house IP counsel, law firms to the stage (give priority to speakers) for this part Q&A.

1800 End of Day 1

1830 Cocktail  (Sponsored  by Womble Bond Dickinson (US) LLP

Day2: 25, Oct. 2018
Day2 Morning: Focus on China


Chairman Opening Remark

Chairman: Li Wu, Senior Consultant, AnJie Law Firm


Pharmaceutical High Value Patent Cultivation

Qiujuan Ma, Director for Pharmaceutical, Patent Examination Cooperation Center of SIPO


Pharmaceutical Patent Trial in China

Chi Su, Director of IP Case Guidance Research (Beijing) Base of the Supreme Peoples Court and President of Beijing IP Law Association; First President, Beijing Intellectual Property Court (Retired in Dec. 2017)


Coffee Break


Topic is Confirming



Challenge and Strategy for China Pharmaceutical IP Department

To prepare the new policies such as patent linkage, regulatory data protection and patent extension, the IP department should take new moves to meet the opportunities. We will invite in-house IP counsel from China to share the suggestion.

aoxi Lin, IP Director, HEC Group


Panel Discussion: Hot Cases of Pharmaceutical Patent Invalidation in China and Implication

Moderator: Li Wu, Senior Consultant, AnJie Law Firm

Panelists are inviting

1235 Lunch

Day2 Afternoon: Focus on EU


The Latest Developments at EPO (including pertinent case law)

Klaus-Peter Döpfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO


The Supplementary Protection Certificate in EU and Potential Modification

The European Commission has collected the public consultation on January 2018, for potential modification of the SPC and patent exemption framework in the EU. SPC is a unique patent protection in EU, and play an important role in innovative pharmaceutical and plant protection products. We will follow this closely.

Andreas Oser, Managing Partner, Prüfer & Partner


Updated Development of Unitary Patent and Unified Patent Court in EU

The 1st edition of "Unitary Patent Guide" was issued in August 2017, providing an outline of the procedure involved in obtaining a Unitary Patent. The Guide also deals with the accessory procedures such as compensation scheme for translation costs, statement on licenses of right, and renewal fees and so on. We will invite EU law firm to introduce the unitary patent, as well as the latest development of UPC.

Jonathan Atkinson, Partner, HGF Limited


Coffee Break


Topic To Be Confirmed

1655 Q&A Session: Practical Tips for Litigation in EU?

It is same as day1 afternoon, we save this part for participants Q&A for their questions in EU. 4-5 guests will be invited to the stage to answer the question (give priority to speakers)

1800 End of Day Two

Day3: 26, Oct. 2018
Day3 Morning: Other Region


Chairman Opening Remark


Pharmaceutical Patent Protection and Patent Term Extension Regime in Japan

Koichiro Morihira, Head of Intellectual Property, Astellas Pharma Inc.

Chair of Intellectual Property Committee, Japan Pharmaceutical Manufacturers Association


Optimizing Overseas Pharma M&A DecisionsBig Data Supported IP Due Diligence

Chieh-Mei Wang, Vice President, ScienbiziP Consulting (Shen Zhen) Co., Ltd.


Coffee Break


The Generic Pharmaceutical in India and Patent Compulsory Licensing System

Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited


Topic is confirming


Conference Closing Remark


  Media Partner